NCT00346164 · CITED IN SOURCE DOCUMENTS

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase: PHASE3
Status at capture: COMPLETED
Registry last update: 2022-04-28

This phase III trial is studying observation to see how well a risk based treatment strategy works in patients with soft tissue sarcoma. In the study, patients are assigned to receive surgery +/- radiotherapy +/- chemotherapy depending on their risk of recurrence. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Probability for Event Free Survival.

→

outcome · POSTED

Toxicity Rate

→

outcome · POSTED

Complete or Partial Response Rate

→

outcome · POSTED

Percent Tumor Necrosis

→

outcome · POSTED

Event Free Survival Probability Disease Extent

→

outcome · POSTED

Event Free Survival Probability Histologic Grade

→

outcome · POSTED

Overall Survival Probability Disease Extent

→

outcome · POSTED

Overall Survival Probability Extent of Resection of the Primary Tumor

→

outcome · POSTED

Incidence of Distant Metastasis

→

outcome · POSTED

Incidence of Distant Metastasis

→

outcome · POSTED

Genetic and Gene Expression Profiles

→

outcome · POSTED

Degree of Agreement in Histologic Grade Determined by the Enrolling Institution Versus by Central Pathology Reviewers

→

outcome · POSTED

Degree of Agreement in Histologic Grade Between Pediatric Oncology Group (POG) and Fédération Nationale Des Centres de Lutte Contre le Cancer (FNCLCC) Pathologic Grading Systems

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Newly diagnosed non-rhabdomyosarcoma soft tissue sarcoma (STS), confirmed by central pathology review via concurrent enrollment on protocol COG-D9902 * Metastatic or non metastatic disease * Meets 1 of the following criteria: * Intermediate (i.e., rarely metastasizing) or malignant STS, including any of the following: * Adipocytic tumor, including liposarcoma of any of the following histology subtypes: * Dedifferentiated * Myxoid * Round cell * Pleomorphic type * Mixed-type * Not otherwise specified (NOS) * Fibroblastic/myofibroblastic tumors, including any of the following: * Solitary fibrous tumor * Hemangiopericytoma * Low-grade myofibroblastic sarcoma * Myxoinflammatory fibroblastic sarcoma * Adult fibrosarcoma\* * Myxofibrosarcoma * Low-grade fibromyxoid sarcoma or hyalinizing spindle-cell tumor * Sclerosing epithelioid fibrosarcoma * So-called fibrohistiocytic tumors, including any of the following: * Plexiform fibrohistiocytic tumor * Giant cell tumor of soft tissues * Pleomorphic malignant fibrous histiocytoma (MFH)/undifferentiated pleomorphic sarcoma * Giant cell MFH/undifferentiated pleomorphic sarcoma with giant cells * Inflammatory MFH/undifferentiated pleomorphic sarcoma with prominent inflammation * Smooth muscle tumor (leiomyosarcoma) * Pericytic \[perivascular\] tumor (malignant glomus tumor or glomangiosarcoma) * Vascular tumor, including angiosarcoma * Chondro-osseous tumors of any of the following types: * Mesenchymal chondrosarcoma * Extraskeletal osteosarcoma * Tumors of uncertain differentiation, including any of the following: * Angiomatoid fibrous histiocytoma * Ossifying fibromyxoid tumor * Myoepithelioma/parachordoma * Synovial sarcoma * Epithelioid sarcoma * Alveolar soft-part sarcoma * Clear cell sarcoma of soft tissue * Extraskeletal myxoid chondrosarcoma ("chordoid type") * Malignant mesenchymoma * Neoplasms with perivascular epithelioid cell differentiation (PEComa) * Clear cell myomelanocytic tumor * Intimal sarcoma * Malignant peripheral nerve sheath tumor * Dermatofibrosarcoma protuberans meeting both of the following criteria: * Non metastatic disease * Tumor must be grossly resected prior to study enrollment * Embryonal sarcoma of the liver * Unclassified STS that is too undifferentiated to be placed in a specific pathologic category (undifferentiated STS or STS NOS) * Gross resection of the primary tumor ≤ 42 days prior to enrollment required except if any of the following circumstances apply: * Non metastatic high-grade tumor \> 5 cm in maximal diameter and gross or microscopic residual tumor is anticipated after resection * Tumor of either high- or- low-grade that cannot be grossly excised without unacceptable morbidity * High-grade tumor with metastases * Patients with metastatic low-grade tumor whose disease is amenable to gross resection at all sites must undergo gross resection of all sites prior to study entry * Patients with a tumor recurrence after a gross total resection are not eligible * Tumors arising in bone are not eligible * Patients with epithelioid sarcoma, clear cell sarcoma, or clinical or radiologic evidence of regional lymph node enlargement must undergo sentinel lymph node biopsies or lymph node sampling to confirm the status of regional lymph nodes\* NOTE: \*Except in cases where the study radiologist reviews the imaging and indicates that a biopsy is not needed to confirm that the patient has lymph node involvement. * If lymph node biopsies are positive for tumor (or the lymph nodes are classified as positive by the study radiologist), formal lymph node dissection must be done at the time of definitive surgery(prior to study entry for patients assigned to study regimen C) * Patients with metastatic disease must undergo a biopsy to confirm the presence of metastatic tumor if all metastases are \< 1 cm in maximal diameter (except in cases where the study radiologist reviews the imaging and indicated that a biopsy is not needed to confirm that the patient has metastatic disease) * Lansky performance status (PS) 50-100% (for patients ≤ 16 years of age) OR Karnofsky PS 50-100% (for patients \> 16 years of age) * Life expectancy ≥ 3 months * Absolute neutrophil count ≥ 1,000/mm³\* * Platelet count ≥ 100,000/mm³\* * Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min (≥ 40 mL/min for infants \< 1 year of age)\* or serum creatinine based on age and/or gender as follows: * 0.4 mg/dL (1 month to \< 6 months of age) * 0.5 mg/dL (6 months to \< 1 year of age) * 0.6 mg/dL (1 year to \< 2 years of age) * 0.8 mg/dL (2 years to \< 6 years of age) * 1.0 mg/dL (6 years to \< 10 years of age) * 1.2 mg/dL (10 years to \< 13 years of age) * 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 years to \< 16 years of age) * 1.7 mg/dL (male) or 1.4 mg/dL (female) (≥ 16 years of age) * Patients with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract * Bilirubin ≤ 1.5 times upper limit of normal (ULN)\* * Shortening fraction ≥ 27% by echocardiogram\* OR ejection fraction ≥ 50% by radionuclide angiogram\* * Not pregnant or nursing (patients undergoing radiotherapy and/or chemotherapy) * No nursing for ≥ 1 month after completion of study treatment in study regimens C or D * Fertile patients must use effective contraception during and for ≥ 1 month after completion of study treatment * Negative pregnancy test * No evidence of dyspnea at rest\* * No exercise intolerance\* * Resting pulse oximetry reading \> 94% on room air (for patients with respiratory symptoms)\* * Prior treatment for cancer allowed provided the patient meet the prior therapy requirements * No prior anthracycline (e.g., doxorubicin or daunorubicin) or ifosfamide chemotherapy for patients enrolled on arm C or arm D * No prior radiotherapy to tumor-involved sites
healthy Volunteers: false
maximum Age: 29 Years
sex: ALL
std Ages: CHILD
ADULT

Treatment arms and interventions

arm Groups

description
Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
intervention Names
Other: clinical observation
Procedure: therapeutic conventional surgery
label
Arm A: No adjuvant treatment
type
EXPERIMENTAL
description
Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
intervention Names
Other: clinical observation
Procedure: therapeutic conventional surgery
Radiation: 3-dimensional conformal radiation therapy
label
Arm B: Low risk; adjuvant radiotherapy
type
EXPERIMENTAL
description
High risk \[metastatic, resected, incompletely resected, or unresected disease\] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
intervention Names
Drug: doxorubicin hydrochloride
Other: clinical observation
Radiation: 3-dimensional conformal radiation therapy
Drug: ifosfamide
label
Arm C: Intermediate & High risk; adjuvant chemoradiotherapy
type
EXPERIMENTAL
description
High risk \[metastatic, resected, incompletely resected, or unresected disease\] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
intervention Names
Drug: doxorubicin hydrochloride
Other: clinical observation
Procedure: therapeutic conventional surgery
Radiation: 3-dimensional conformal radiation therapy
Drug: ifosfamide
label
Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy
type
EXPERIMENTAL

interventions

arm Group Labels
Arm C: Intermediate & High risk; adjuvant chemoradiotherapy
Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy
description
Given IV
name
doxorubicin hydrochloride
other Names
ADM
ADR
Adria
Adriamycin PFS
Adriamycin RDF
type
DRUG
arm Group Labels
Arm A: No adjuvant treatment
Arm B: Low risk; adjuvant radiotherapy
Arm C: Intermediate & High risk; adjuvant chemoradiotherapy
Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy
description
Patients undergo observation
name
clinical observation
other Names
observation
type
OTHER
arm Group Labels
Arm A: No adjuvant treatment
Arm B: Low risk; adjuvant radiotherapy
Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy
description
Patients undergo surgery
name
therapeutic conventional surgery
type
PROCEDURE
arm Group Labels
Arm B: Low risk; adjuvant radiotherapy
Arm C: Intermediate & High risk; adjuvant chemoradiotherapy
Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy
description
Patients undergo radiotherapy
name
3-dimensional conformal radiation therapy
other Names
3D conformal radiation therapy
3D-CRT
type
RADIATION
arm Group Labels
Arm C: Intermediate & High risk; adjuvant chemoradiotherapy
Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy
description
Given IV
name
ifosfamide
other Names
Cyfos
Holoxan
IFF
IFX
IPP
type
DRUG

Study design

allocation

NON_RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 588
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Probability of no relapse, secondary malignancy or death after 5 years since enrollment.
measure
Probability for Event Free Survival.
time Frame
5 years

secondary Outcomes

description
Percentage of Arm D patients experiencing grade 4+ adverse events.
measure
Toxicity Rate
time Frame
13 weeks
description
Tumor response by imaging. Complete Response (CR): Complete disappearance of the tumor. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Overall Response (OR)=CR+PR.
measure
Complete or Partial Response Rate
time Frame
13 weeks
description
Percent tumor necrosis by pathology review.
measure
Percent Tumor Necrosis
time Frame
13 weeks
description
Probability of no relapse, secondary malignancy or death after 5 years since enrollment.
measure
Event Free Survival Probability Disease Extent
time Frame
5 years
description
Probability of no relapse, secondary malignancy or death after 5 years since enrollment
measure
Event Free Survival Probability Histologic Grade
time Frame
5 years
description
Probability of survival after 5 years since enrollment.
measure
Overall Survival Probability Disease Extent
time Frame
5 years
description
Probability of survival after 5 years since enrollment.
measure
Overall Survival Probability Extent of Resection of the Primary Tumor
time Frame
5 years
description
Percent of patients who had distant metastasis.
measure
Incidence of Distant Metastasis
time Frame
Up to 10 years
description
The tumors from patients registered on D9902 will be analyzed for genetic and gene expression profiles. The study will prospectively evaluate each tumor and confirm newly defined sarcoma diagnostic criteria based on cancer signatures in NRSTS.
measure
Genetic and Gene Expression Profiles
time Frame
At diagnosis
description
Histologic grades were determined by the central pathology reviewers and institutional pathologists based on published standards. A higher grade is associated with a more severe disease.
measure
Degree of Agreement in Histologic Grade Determined by the Enrolling Institution Versus by Central Pathology Reviewers
time Frame
At Diagnosis
description
POG and FNCLCC grades were determined by pathologists based on published standards. A higher grade is associated with a more severe disease.
measure
Degree of Agreement in Histologic Grade Between Pediatric Oncology Group (POG) and Fédération Nationale Des Centres de Lutte Contre le Cancer (FNCLCC) Pathologic Grading Systems
time Frame
At diagnosis

Full study description

brief Summary: This phase III trial is studying observation to see how well a risk based treatment strategy works in patients with soft tissue sarcoma. In the study, patients are assigned to receive surgery +/- radiotherapy +/- chemotherapy depending on their risk of recurrence. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.
detailed Description: PRIMARY OBJECTIVES: I. Define a risk-based treatment strategy comprising observation only, adjuvant radiotherapy, or adjuvant chemoradiotherapy or neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy in young patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). II. Assess event-free and overall survival of patients treated with these regimens. III. Assess the pattern of treatment failure in these patients. SECONDARY OBJECTIVES: I. Assess the feasibility of a neoadjuvant chemoradiotherapy approach in patients with intermediate- or high-risk NRSTS. II. Assess the imaging and pathologic responses to neoadjuvant chemoradiotherapy in patients with intermediate- or high-risk NRSTS. III. Correlate imaging and pathologic response with clinical outcomes in patients with intermediate- or high-risk disease who undergo neoadjuvant chemoradiotherapy. IV. Prospectively define clinical prognostic factors associated with event-free survival, overall survival, local recurrence, and distant recurrence in these patients. V. Correlate patient outcomes with findings of biologic studies performed on tissue specimens collected on protocol COG-D9902 from these patients. VI. Determine whether the diagnosis and histologic grade of NRSTS assigned by the enrolling institution correlates with the diagnosis and histologic grade established by central expert pathology reviewers. VII. Compare the Pediatric Oncology Group (POG) and Fédération Nationale des Centres de Lutte Contre le Cancer (French Federation of Cancer Centers \[FNCLCC\]) pathologic grading systems to determine which better correlates with clinical outcomes. OUTLINE: This is a multicenter study. Patients are divided into 3 risk groups according to presence of metastatic disease (yes vs no), status of prior surgery (resected vs unresected), grade of tumor (low vs high), and size of primary tumor (≤ 5 cm vs \> 5 cm). Patients are assigned to different treatment regimens based on disease extent (nonmetastatic vs metastatic), tumor size (≤ 5 cm vs \> 5 cm), extent of resection of primary tumor (resected vs unresected), extent of resection of metastases (complete or microscopic residual vs gross residual), microscopic tumor margins (negative vs positive), and tumor grade (low vs high). GROUP 1 (low risk \[nonmetastatic, grossly resected disease, except high-grade tumor \> 5 cm\]): Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to regimen A. Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to regimen B. REGIMEN A (observation only): Patients undergo observation only. REGIMEN B (adjuvant radiotherapy): Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy. GROUP 2 (intermediate risk \[nonmetastatic, resected or unresected disease\]): Patients with grossly resected, high-grade tumor \> 5 cm (in maximum diameter) are assigned to regimen C. Patients with unresected tumor are assigned to regimen D. REGIMEN C (adjuvant chemoradiotherapy): Patients receive ifosfamide IV over 3 hours on days 1-3 in weeks 1, 4, 7, 10, 13, and 16 and doxorubicin hydrochloride IV over 24 hours on days 1 and 2 in weeks 1, 4, 13, 16, and 19. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. \*NOTE: \*Patients who receive brachytherapy will initiate radiotherapy in Week 1. If brachytherapy is administered, chemotherapy should begin within 2 weeks of completion of brachytherapy and the Weeks 1 and 19 doxorubicin should be given instead at Weeks 7 and 10. REGIMEN D (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Neoadjuvant chemoradiotherapy and surgery: Patients receive ifosfamide IV over 3 hours on days 1-3 in weeks 1, 4, 7, and 10 and doxorubicin hydrochloride IV over 24 hours on days 1 and 2 in weeks 1 and 4. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy\*\*. Patients undergo surgical resection in week 13. NOTE: \*\*Patients with primary hepatic tumors do not receive radiotherapy in week 4. Adjuvant chemotherapy with or without radiotherapy: Patients receive ifosfamide IV over 3 hours on days 1-3 in weeks 16 and 19 and doxorubicin hydrochloride IV over 24 hours on days 1 and 2 in weeks 16, 19\*\*\*, and 22. Beginning in week 16, patients achieving gross total resection with positive microscopic margins undergo a total of 6 fractions of adjuvant radiotherapy. Patients achieving less than total gross resection undergo a total of 11 fractions of adjuvant radiotherapy. Patients achieving total gross resection with negative microscopic margins do not receive adjuvant radiotherapy. NOTE: \*\*\*Patients who receive adjuvant radiotherapy in week 16 receive doxorubicin hydrochloride in week 25 instead of week 19. GROUP 3 (high risk \[metastatic, resected, incompletely resected, or unresected disease\]): Patients with low-grade, all-sites resected tumor with either negative or positive microscopic margins are assigned to receive treatment as in group 1 regimen A. Patients with high-grade, grossly resected primary tumor, and metastatic disease are assigned to receive treatment as in group 2 regimen C. Patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in group 2 regimen D. In all groups, treatment continues in the absence of disease progression. After completing study treatment, patients are followed periodically for at least 5 years.

Source references

references

citation
Crane JN, Xue W, Qumseya A, Barkauskas DA, Chau K, Tan SY, Hiniker S, Dasgupta R, Venkatramani R, Spunt SL, Weiss AR, Laetsch TW. Malignant peripheral nerve sheath tumors: a report from Children's Oncology Group study ARST0332. J Natl Cancer Inst. 2026 May 1;118(5):829-838. doi: 10.1093/jnci/djaf359.
pmid
41386267
type
DERIVED
citation
Alvarez E, He J, Spunt SL, Hayes-Jordan A, Kao SC, Parham DM, Million L, Weiss AR, Barkauskas DA. Lymph node metastases in paediatric and young adult patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Findings from Children's Oncology Group (COG) study ARST0332. Eur J Cancer. 2023 Feb;180:89-98. doi: 10.1016/j.ejca.2022.11.014. Epub 2022 Nov 25.
pmid
36566574
type
DERIVED
citation
Venkatramani R, Xue W, Randall RL, Wolden S, Anderson J, Lopez-Terrada D, Black J, Kao SC, Shulkin B, Ostrenga A, Pappo A, Spunt SL. Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study. J Clin Oncol. 2021 Dec 10;39(35):3927-3937. doi: 10.1200/JCO.21.01628. Epub 2021 Oct 8.
pmid
34623899
type
DERIVED
citation
Million L, Hayes-Jordan A, Chi YY, Donaldson SS, Wolden S, Morris C, Terezakis S, Laurie F, Morano K, Fitzgerald TJ, Yock TI, Rodeberg DA, Anderson JR, Speights RA, Black JO, Coffin C, McCarville MB, Kao SC, Hawkins DS, Spunt SL, Randall RL. Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Childrens Oncology Group. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):821-830. doi: 10.1016/j.ijrobp.2021.01.051. Epub 2021 Feb 3.
pmid
33548339
type
DERIVED
citation
Spunt SL, Million L, Chi YY, Anderson J, Tian J, Hibbitts E, Coffin C, McCarville MB, Randall RL, Parham DM, Black JO, Kao SC, Hayes-Jordan A, Wolden S, Laurie F, Speights R, Kawashima E, Skapek SX, Meyer W, Pappo AS, Hawkins DS. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncol. 2020 Jan;21(1):145-161. doi: 10.1016/S1470-2045(19)30672-2. Epub 2019 Nov 27.
pmid
31786124
type
DERIVED
citation
Spunt SL, Francotte N, De Salvo GL, Chi YY, Zanetti I, Hayes-Jordan A, Kao SC, Orbach D, Brennan B, Weiss AR, van Noesel MM, Million L, Alaggio R, Parham DM, Kelsey A, Randall RL, McCarville MB, Bisogno G, Hawkins DS, Ferrari A. Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials. Eur J Cancer. 2019 May;112:98-106. doi: 10.1016/j.ejca.2019.02.001. Epub 2019 Apr 5.
pmid
30954717
type
DERIVED
citation
Ferrari A, Chi YY, De Salvo GL, Orbach D, Brennan B, Randall RL, McCarville MB, Black JO, Alaggio R, Hawkins DS, Bisogno G, Spunt SL. Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma: A joint analysis from the European paediatric soft tissue sarcoma Study Group and the Children's Oncology Group. Eur J Cancer. 2017 Jun;78:1-6. doi: 10.1016/j.ejca.2017.03.003. Epub 2017 Apr 7.
pmid
28391003
type
DERIVED